Skip to main content

Lost in translation: Why resveratrol supplements are not the same as drinking wine


Resveratrol, the miracle molecule from red wine, has rocketed from relative obscurity to celebrity status in the supplement market. Its multiple anti-aging properties are given credit for this, and I used resveratrol research in my book “Age Gets Better with Wine” to explain why moderate regular consumption of red wine is a healthy thing. Supplement marketers now proclaim that resveratrol pills have “all the benefits of wine without the alcohol” and tout their own special formulas. Yet there remains a lack of large well-controlled clinical studies to back up these claims.

A relatively new field of medical science called translational medicine helps explain the problem. Often called “bench to bedside” research, translational medicine seeks to bridge the gap between laboratory studies and validated clinical treatments. The challenge of translational medicine is enormous, given that more than 90% of treatments (say for example a drug or supplement) fail in human trials after successful runs in animal studies. It’s an astonishing  statistic, but this percentage has actually been increasing despite improvements in methodology. Dr. Richard Klausner, former Director of the National Cancer Institute, summed up the problem: “We have cured cancer in mice for decades—and it simply didn’t work in humans.”

So what does this mean for resveratrol? Despite the thousands of scholarly publications on resveratrol, it is still not clear. If you are a fruit fly, then resveratrol will activate your anti-aging sirtuin genes and you will live longer (and apparently have a more vigorous sex life.) If you are a mouse on a high fat diet, resveratrol is what you want in order to set your metabolism in order. But translating these findings to humans is deceptively difficult. A recent article highlighted some of the problems: Natural compounds such as resveratrol afford no intellectual property that could be leveraged to fund the large clinical trials needed to determine their effectiveness; nutraceutical companies complicate the problem further by developing their own proprietary blends with multiple ingredients; and resveratrol has multiple therapeutic “targets” each with its own dose-response curve, tissue affinity, and metabolism.

Resveratrol research may still pan out however, and some therapeutic applications are well validated, such as in skin care. Evidence is certainly adequate to continue with clinical research on resveratrol on a wide range of conditions, including Alzheimer’s disease, diabetes, and cardiovascular disease. But a glass of red wine with dinner is still a good thing and likely to remain so.

Comments

  1. Typical Resveratrol supplements are made from Japanese knotweed, which contains only trans-resveratrol. Just 100mg of Vineatrol Mixed Resveratrol offers you more benefits than 100 glasses of red wine and has 20 times the potency of ordinary trans-Resveratrol supplements. Read more at:
    http://kidbuxblog.com/trigger-your-longevity-gene-with-resveratrol/

    ReplyDelete

Post a Comment

Popular posts from this blog

Wear red and DRINK red for women’s heart health

This Friday Feb 2nd is the annual “wear red” day in Canada and the U.S. to raise awareness for women’s heart health. Why only a day for the number one threat to women’s health? Women are 5 times more likely to succumb to heart disease than breast cancer, which gets a whole month (October.) Another contradiction is that the advice women hear about prevention of breast cancer is the opposite of what you can do to lower the risk of heart disease: a daily glass of wine. Even one drink a day raises your risk of breast cancer, we are told, ignoring the overriding benefits of wine on heart health. Drink red wine to live longer Here’s why I think women should also “drink red.” For starters, wine helps de-stress and celebrates life. Stress is a factor in heart disease, and if that were the only way wine helped it would be worth considering. But the medical evidence is also strong: a daily glass of red wine helps raise the HDL “good cholesterol” levels, which lowers the risk of cardiovascular p…

Which types of wine are the healthiest?

I am often asked after lecturing on the healthful properties of wine which type is best to drink. Since much of the discussion has to do with the polyphenol antioxidants from the skins and seeds of the grape, red wine is the first criterion since it is fermented with the whole grape rather than the pressed juice. This allows for extraction and concentration of these compounds, familiar ones being resveratrol and tannins. But beyond that, which varietals have the highest concentrations?


According to the Roman philosopher Pliny the Elder, “The best kind of wine is that which is pleasant to him that drinks it” but modern science expects more specifics. (The point of course is that if you have a wine that you enjoy you are more likely to drink regularly and therefore reap the benefits.) But there are several difficulties in singling out certain wines for their healthful properties. Which compounds to measure? Are we talking about heart health or the whole gamut? Is it the varietal of the …

The J-curve is dead. Long live the J-curve!

There is a resurgence of debate about the validity of the J-curve, especially as it relates to alcohol and cancer. A 2014 report determined that “alcohol use was positively associated with overall mortality, alcohol-related cancers, and violent death and injuries, but marginally to CVD/CHD” (cardiovascular disease). In other words, there was little benefit if any in terms of heart disease but a big upside risk for cancer and accidental or violent demise. Gone was the French Paradox! The J curve is dead! Or not. Though that statement may be technically true, I looked at look at the data myself and found something different: a strong confirmation of the J-curve for overall mortality, overall cancer deaths, cardiovascular disease, and all “other causes.” This held for both men and women:
    Used under creative commons license from Ferrari P, Licaj I,Muller DC, et al. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and nu…